A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
Status:
Completed
Trial end date:
2018-08-29
Target enrollment:
Participant gender:
Summary
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of
glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic
hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis
respectively.